3 results
Approved WMOCompleted
To demonstrate superiority with regard to Progression Free Survival based on an Independent Review Committeeassessment of avelumab versus platinum-based doublet in NSCLC subjects with PD-L1+
Approved WMOCompleted
With this proof-of-concept study, we will address i. differences in dopamine release in T2DM patients versus historical lean controls, ii. whether timed restoring of dopamine signalling improves dopamine release and iii. whether this reinstatement…
Approved WMOCompleted
Objectives:Primary Objective: to investigate the anti-tumor efficacy of domatinostat in combination with avelumab in advanced unresectable/metastatic MCC patients progressing on anti-PD-(L)1 antibody monotherapy.Secondary Objectives: to investigate…